Advertisement

Paclitaxel

  • Ines Mader
  • Patrizia E. Fürst-Weger
  • Robert M. Mader
  • Elisabeth I. Semenitz
  • Robert Terkola
  • Sabine M. Wassertheurer

Keywords

Natl Cancer Inst Sodium Cromoglycate Clin Drug Invest Radiation Recall Silver Sulfadiazine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Original articles

  1. [1]
    DuBois A, Kommoss FG, Pfisterer J, et al: Paclitaxel-induced “recall” soft tissue ulcerations occurring at the site of previous subcutaneous administration of paclitaxel in low doses. Gynecol Oncol 60: 94–96, 1996.CrossRefGoogle Scholar
  2. [2]
    Bertelli G, Cafferata MA, Ardizzoni A, et al: Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer 79: 2266–2268, 1997.PubMedCrossRefGoogle Scholar
  3. [3]
    Raymond E, Cartier S, Canuel C, et al: Extravasation de paclitaxel (Taxol®). Rev Méd Interne 16: 141–142, 1995.PubMedCrossRefGoogle Scholar
  4. [4]
    Goodman M, Stewart I, Lydon J, et al: Use caution when managing paclitaxel and taxotere infiltrations. Oncol Nurs Forum 23: 541–542, 1996.PubMedGoogle Scholar
  5. [5]
    Bicher A, Levenback C, Burke TW, et al: Infusion site soft-tissue injury after paclitaxel administration. Cancer 76: 116–120, 1995.PubMedCrossRefGoogle Scholar
  6. [6]
    Kane MP, Medina PJ, Aisner J: Vesicant reaction to paclitaxel extravasation. J Oncol Pharm Practice 4: 45, 1998.CrossRefGoogle Scholar
  7. [7]
    Herrington JD, Figueroa JA: Severe necrosis,clue to paclitaxel extravasation. Pharmacotherapy 17: 163–165, 1997.PubMedGoogle Scholar
  8. [8]
    DuBois A, Fehr MK, Bochtler H, et al: Clinical course and management of paclitaxel extravasation. Oncol Rep 3: 973–974, 1996.PubMedGoogle Scholar
  9. [9]
    Ajani JA, Dodd LG, Daugherty K, et al: Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. J Natl Cancer Inst 86: 51–53, 1994.PubMedCrossRefGoogle Scholar
  10. [10]
    Meehan JL, Sporn JR: Case report of taxol administration via central vein producing a recall reaction at a site of prior taxol extravasation. J Natl Cancer Inst 86: 1250–1251, 1994.PubMedCrossRefGoogle Scholar
  11. [11]
    Riedel U, Serke M, Schönfeld N, et al: Extravasation of paclitaxel (Taxol®) — clinical course. Onkologie 22: 318–320, 1999.CrossRefGoogle Scholar
  12. [12]
    Shapiro J, Richardson GE: Paclitaxel-induced „recall“ soft tissue injury occuring at the site of previous extravasation with subsequent intravenous treatment in a different limb. J Clin Oncol 12: 2237–2238, 1994.PubMedGoogle Scholar
  13. [13]
    Panday VR, Huizing MT, Huinink WW, et al: Hypersensitivity reactions to the taxanes paclitaxel and docetaxel. Clin Drug Invest 14: 418–427, 1997.CrossRefGoogle Scholar
  14. [14]
    Stein ME, Drumea K, Abu-Rasmi R, et al: Taxol-induced cellulitis after extravasation: a rarely reported event. Am J Clin Oncol 20: 540, 1997.PubMedCrossRefGoogle Scholar
  15. [15]
    Hidalgo M, Benito J, Colomer R, et al: Recall reaction of a severe local peripheral neuropathy after paclitaxel extravasation. J Natl Cancer Inst 88: 13–20, 1996.CrossRefGoogle Scholar
  16. [16]
    Berghmans T, Klastersky J: Paclitaxel-induced cutaneous toxicity. Support Care Cancer 3: 203–204, 1995.PubMedCrossRefGoogle Scholar
  17. [17]
    Bailey WL, Crump RM: Taxol extravasation: a case report. Can Oncol Nurs J 7: 96–99, 1997.PubMedGoogle Scholar
  18. [18]
    Dorr RT, Snead K, Liddil JD: Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer 78: 152–156, 1996.PubMedCrossRefGoogle Scholar

Secondary literature

  1. [19]
    van Gemmern R: Gewebstoxizität und Paravasatbehandlung neuer Zytostatika. Krankenhauspharmazie 17: 471–473, 1996.Google Scholar
  2. [20]
    Bristol-Myers Squibb, personal communication, November 1998.Google Scholar
  3. [21]
    Gain M, Melzer S, Meyer-Jürshof A, et al: Paclitaxel: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 3: 41, 1998.Google Scholar
  4. [22]
    Dorr RT: Author reply to Bertelli G, et al: Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer 79: 2268–2269, 1997.CrossRefGoogle Scholar
  5. [23]
    Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.Google Scholar
  6. [24]
    Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.Google Scholar
  7. [25]
    Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.PubMedCrossRefGoogle Scholar
  8. [26]
    Bokemeyer C: Dermatoxizität antineoplastischer Substanzen. In: Schmoll HJ, Höffken K, Possinger K (eds) Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie. Springer, Vol 1, 3rd edition: 1411–1426, 1999.Google Scholar
  9. [27]
    Berdel WE, Schmoll HJ, Michele T, et al: Prävention und Therapie von Paravasaten/Extravasaten. In: Schmoll HJ, Höffken K, Possinger K (eds) Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie. Springer, Vol 1, 3rd edition: 1689–1701, 1999.Google Scholar
  10. [28]
    Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.Google Scholar
  11. [29]
    Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.Google Scholar
  12. [30]
    Rogers BB: Nursing implications in the administration of paclitaxel (Taxol®). Semin Oncol Nurs 9: 11–15, 1993.PubMedGoogle Scholar
  13. [31]
    Raghavan VT, Bloomer WD, Merkel DE: Taxol and radiation recall dermatitis. Lancet 341: 1354, 1993.PubMedCrossRefGoogle Scholar
  14. [32]
    Rowinsky EK, Eisenhauer EA, Chaudhry V, et al: Clinical toxicities encountered with paclitaxel (Taxol®). Semin Oncol 20 (Suppl 3): 1–15, 1993.PubMedGoogle Scholar
  15. [33]
    Barth J: Paravasate und deren Behandlung. In: Barth J (ed) ZytostatikaHerstellung in der Apotheke. Deutscher Apotheker Verlag, chapter VI-3: 1–9, 2000.Google Scholar
  16. Further readingGoogle Scholar
  17. —.
    Lorenz W, Reimann HJ, Schmal A, et al: Histamine release in dogs by Cremophor® EL and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 7: 63–67, 1977.PubMedCrossRefGoogle Scholar

Further reading

  1. —.
    Noone MH, McCabe MS, Denicoff AM, et al: Nursing management of the patient receiving taxol therapy. J Natl Cancer Inst Monogr 15: 149–154, 1993.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Ines Mader
    • 1
  • Patrizia E. Fürst-Weger
    • 2
  • Robert M. Mader
    • 3
  • Elisabeth I. Semenitz
    • 4
  • Robert Terkola
    • 5
  • Sabine M. Wassertheurer
    • 6
  1. 1.Austrian Breast and Colorectal Cancer Study GroupViennaAustria
  2. 2.SMZ FloridsdorfKrankenhaus und GeriatriezentrumViennaAustria
  3. 3.Clinical Division of Oncology, Department of Medicine IUniversity HospitalViennaAustria
  4. 4.AnstaltsapothekeLandeskrankenhaus — Universitätskliniken InnsbruckAustria
  5. 5.Kaiser-Franz-Josef HospitalViennaAustria
  6. 6.Apotheke LKH-Univ.-Klinikum GrazAustria

Personalised recommendations